viatris among three companies licensed to make gsk/pfizer-backed long acting hiv prevention drug. sublicence agreements with

pfizer unusual options activity. a whale with a lot of money to spend has taken a noticeably ish stance on looking at options history for pfizer (nyse:) we detected 10 strange trades. if we consider the specifics of each trade it is accurate to state t

noteworthy tuesday option activity: pfe glpi nvcr. looking at options trading activity among components of the russell 3000 index there is noteworthy activity today in pfizer inc (symbol: pfe) where a total volume of 119138 contracts has bee

pfizer-backed pyxis oncology surges 48% to hit 11-month high.

pfizer and merck kgaa end global collaboration for cancer therapy bavencio.

deere and pfizer have been highlighted as zacks and bear of the day. for immediate releasechicago il &ndash. march 27 2023 &ndash. zacks equity research shares deere &. company de as the of the day and pfizer pfe as the bear of th

bear of the day: pfizer inc. (pfe). the zacks medical sector has struggled in 2023 down roughly 5% ytd and underperforming relative to the s&.p 500.

pfizer signs agreement with china on improving health coverage in the country. United States pharma giant pfizer has signed an agreement with china to cooperate on improving the countrys health coverage according to the company.

pfizers covid drug paxlovid may reduce the risk of developing long covid study says. people who took pfizers antiviral treatment paxlovid shortly after infection saw a 26% lower risk of long covid compared with those who didnt the study said.

pfizer (pfe) investor presentation - slideshow.

why pfizer likely isnt done with m&a after the seagen deal. pfizer (nyse: pfe) has been a company on a mission looking to restock its pipeline with growth opportunities as its covid-19 revenue declines this year and beyond. in the past year it h

guru fundamental report for pfe - peter lynch. below is valideas guru fundamental report for pfizer inc. (pfe). of the 22 guru strategies we follow pfe rates highest using our p/e/growth investor model based on the published strategy of peter l

insiders selling pfizer and 2 other stocks. the nasdaq composite traded slightly higher on monday. investors meanwhile focused on some notable insider trades. when insiders sell shares it indicates their concern in the company&rsquo.s prospects or that t

wipro among 2 it stocks at 52-week lows. heres why. meanwhile amid concern over us markets pharma stocks were also under pressure. shares of gland pharma lupin and granules india declined 2-2.5% in mondays trade. aurobindo pharma pfizer zydus lifesciences

insiders selling pfizer and 2 other stocks.

the nasdaq composite traded slightly higher on monday. investors, meanwhile, focused on some notable insider trades.

when insiders sell shares, it indicates their concern in the company’s prospe

insiders selling pfizer and 2 other stocks.

the nasdaq composite traded slightly higher on monday. investors, meanwhile, focused on some notable insider trades.

when insiders sell shares, it indicates their concern in the company’s prospe

insiders selling pfizer and 2 other stocks.

the nasdaq composite traded slightly higher on monday. investors, meanwhile, focused on some notable insider trades.

when insiders sell shares, it indicates their concern in the company’s prospe

insiders selling pfizer and 2 other stocks.

the nasdaq composite traded slightly higher on monday. investors, meanwhile, focused on some notable insider trades.

when insiders sell shares, it indicates their concern in the company’s prospe

pfizers (pfe) covid-19 drug paxlovid gets fda panel vote. pfizer inc.pfe announced that the fda&rsquo.s antimicrobial drugs advisory committee (amdac) voted 16 to 1 in favor of paxlovid for the treatment of mild-to-moderate covid-19 in

pharma stock roundup: m&a boom in drug industry with pfe & sny deals other updates. this week m&.a activity picked up momentum in the drug and biotech sector with pfizer pfe announcing a huge $43 billion offer for another cancer dru

pfizer astellas tout positive xtandi data to potentially expand label for the prostate cancer drug. ) and)

pfizer working to develop new packaging for migraine drug over child safety poisoning concerns. )prescription migraine drugs nurtec odt 75 mg orally disintegratin

oric pharmaceuticals reports fourth quarter and full year 2022 financial results and operational updates. initial phase 1b data for three ongoing clinical trials expected in second half of 2023: oric-533 in multiple myeloma oric-114 in egfr/her2-mutated

fda advisors recommend full approval of pfizer covid treatment paxlovid for adults 50 and over and other high-risk people. paxlovid is recommended for people over 50 or those with medical conditions like high blood pressure or diabetes that place them at

pfizer wins fda panel vote for full approval of covid pill.

fda says pfizer covid pill eua for adolescents to stay even after nod for adults. the United States health regulator said on thursday the current emergency use authorization (eua) for pfizers covid-19 antiviral pill for high-risk adolescents wil

pfizer recalls migraine drug over packaging issues - cpsc. pfizer inc has recalled about 4.3 million units of its migraine drug nurtec odt as its packaging is not child-resistant and poses a risk of poisoning United States consumer product safet

pfizer recalls 4.2m units of migraine therapy over packaging defect.

fda says pfizers covid pill to stay authorized for adolescents after approval for adults. the United States health regulator said on thursday the current emergency authorization for pfizers covid-19 antiviral pill for adolescents will continue t